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Abstract 
 The whole-body deletion of small heterodimer partner (SHP) in mice is associated with 
protection from diet-induced obesity and hepatic steatosis upon feeding of a western diet.  This 
protection was reported to be mediated through decreases in hepatic gene expression for 
lipogenesis, as well as increases in gene expression for fatty acid oxidation.  SHP has been 
known to regulate the expression of the CYP7A1 gene, encoding the rate-limiting enzyme for 
bile acid synthesis, thereby altering the bile acid pool.  The effects of this altered bile acid profile 
on the gut microbiome are unknown, as some bacteria in the gut are responsible for bile acid 
metabolism while others are killed by the detergent effect of bile acids.  This study shows that 
mice without SHP display a distinctly different microbiome from wild-type mice, characterized 
by a reduction of phylogenetic diversity and an increased abundance of the Bacteroidetes 
phylum with a proportional decrease in Firmicutes abundance.  Cohousing mice led to increased 
microbiome similarity between genotypes, with a blunted reduction of phylogenetic diversity in 
SHP-/- mice.  Furthermore, cohoused mice displayed reductions in the hepatic gene expression 
for synthesis of fatty acids, lipid droplets, and bile acids without altering fat and liver mass.  
These results may suggest a relationship between SHP and the microbiome in the development 
of diet-induced obesity but not hepatic steatosis. 
 
Introduction 
  Small heterodimer partner (SHP) is an orphan nuclear hormone receptor involved in the 
regulation of glucose and lipid metabolism homeostasis [1].  SHP does not bind DNA due to a 
lack of DNA binding domains; it represses transcription through interactions with other 
transcription factors [1, 3].  As SHP is involved in the negative feedback regulation of bile acid 
synthesis, the deletion of SHP leads to increased expression of genes involved in bile acid 
synthesis [3].  Upon feeding of a western diet (WD) containing high fat, carbohydrate, and 
cholesterol, SHP-/- mice displayed reduced fat accumulation in the liver [1].  Protection from 
diet-induced obesity (DIO) is also associated with the SHP-/- genotype through increased energy 
expenditure from brown adipose tissue, and increased β-oxidation gene expression reduces the 
accumulation of triglyceride lipid droplets in liver cells (hepatic steatosis) [1, 5].  Hepatic 
steatosis is commonly associated with insulin resistance and other metabolic disorders such as 
DIO and type 2 diabetes [6, 7].  More than 75% of obese patients and 25% of the general 
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population are affected by this disorder [6, 8].  Hepatic steatosis can progress to nonalcoholic 
fatty liver disease when an excess of free fatty acids triggers lipotoxicity and activates 
inflammatory pathways, and progression to nonalcoholic steatohepatitis occurs when 
inflammation and fibrosis causes damage to the hepatocytes [6, 9]. 
 The gut microbiota also plays a major role in metabolism and formation of DIO [10].  
The phyla Bacteroidetes and Firmicutes, which represent over 90% of the bacterial species in 
both mice and humans, are partially responsible for the energy released from the diet [11].  
Traditionally, lean subjects display decreased populations of Firmicutes and increased 
Bacteroidetes, while obese subjects display increased populations of Firmicutes and decreased 
Bacteroidetes with reductions in overall diversity of the microbiome [12].  Gut bacteria are also 
involved in the metabolism of bile acid through the deconjugation, dehydrogenation, and 
dehydroxylation of primary bile acids for use in anaerobic fermentation [7].  In addition to 
providing energy for bacterial metabolism, the metabolism of primary bile acids forms secondary 
bile acids with altered antibacterial properties [13, 14].  Through detergent properties, bile acids 
can disrupt the lipid bilayer of bacterial cell membranes and damage arrangements of nucleic 
acids and proteins [15].  Several Bacteroides, Lactobacillus, and Bifidobacterium species are 
well known for their role in deconjugation of hydrophobic primary bile acids to produce 
secondary bile acids with reduced antibacterial effect [15, 16].  Dehydroxylation of primary bile 
acids performed by members of genus Eubacterium and Clostridium produces secondary bile 
acids of higher hydrophobicity, which therefore increases the antibacterial effect [16].  Bacterial 
susceptibility to bile acid-mediated damage is widely variable depending on species and 
environment [13, 16]. 
 SHP represses bile acid synthesis through its action on the liver enzymes in the 
cytochrome P450 family, CYP7A1 and CYP8B1 [1].  CYP7A1 hydroxylates cholesterol as the 
rate-limiting first enzyme for the classical pathway of bile acid synthesis, followed by CYP8B1 
to produce cholic acid, a hydrophilic primary bile acid [1, 14, 17].  The hydrophobic primary bile 
acid, chenodeoxycholic acid, can also be produced from CYP7A1 without CYP8B1, or through 
CYP7B1 in an alternate pathway [17].  Mice then convert chenodeoxycholic acid to α- and β-
muricholic acid to complete the synthesis process (Supp. Fig. 1) [18].  After synthesis, these 
primary bile acids are conjugated in mice using dietary taurine before being secreted from the 
liver for storage in the gallbladder [14].  Following release from the gallbladder and passage 
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through the intestines, intestinal enterocytes reabsorb approximately 95% of the bile acids for 
return to the liver using the circulatory system, where the remainder is lost into feces [15, 19].  
Once returned to hepatocytes, FXR is activated and induces SHP to inhibit CYP7A1 as a 
negative feedback loop on bile acid synthesis [20].  SHP further inhibits cholic acid production 
through repression of CYP8B1, also of the classical synthesis pathway [19].  The deletion of 
SHP leads to increased production of hydrophilic bile acids through derepression of both 
CYP7A1 and CYP8B1, causing higher production of cholic acid with reduced production of both 
α- and β-muricholic acid [3, 20, 21]. 
  SHP also influences hepatic expression of genes involved in de novo fatty acid synthesis 
and lipid accumulation.  The transcription factor SREBP-1c activates the fatty acid synthesis 
pathway in response to insulin, allowing FAS downstream to build the saturated fatty acid 
palmitate from acetyl-CoA and malonyl-CoA [22, 23].  While these fatty acids can be used to 
synthesize cell membranes and other intracellular components, their abnormal accumulation 
inside hepatocytes can inhibit glucose uptake and lead to insulin resistance or the formation of 
steatosis [22, 23].  WD feeding leads to increased fatty acid synthase (Fasn) expression to 
produce fatty acids [24-26].  CIDEC also promotes the formation of lipid droplets from buildup 
of these intracellular fatty acids [24, 27].  The deletion of SHP protects from hepatic steatosis by 
inhibiting CIDEC activation and upregulating the gene expression of CPT1A and ACOX1, 
involved in the β-oxidation of fatty acids [1, 28, 29].  CPT1A facilitates transport of long-chain 
fatty acids into the mitochondria for β-oxidation, and ACOX1 oxidizes very long-chain fatty 
acids that are esterified with CoA to begin the β-oxidation process in the peroxisome [25, 30]. 
 Previous studies have shown that the deletion of SHP increases the amount of hydrophilic 
bile acids in the pool, which is predicted to affect the structure of the microbiome [3, 13-15].  
Therefore, 16S tag pyrosequencing was utilized to elucidate the specific effects of SHP deletion 
on the gut bacteria, and also to confirm the similarities in microbiome composition associated 
with cohousing mice.  Cohousing both genotypes together alleviates the difference in diversity 
between genotypes, and these mice also display reduced expression of hepatic genes for β-
oxidation, and synthesis of fatty acids, lipid droplets, and bile acids.  Targeting the impacts of 
SHP gene expression will also help elucidate the impact of the SHP-dependent pathway of bile 
acid regulation, and perhaps even provide greater insight into other factors involved in the 
increased protection of SHP-/- mice from DIO and hepatic steatosis [1].  The relationship of 
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phenotypic changes associated with alterations in the gut microbiome in mice lacking SHP is 
also unknown.  This study shows that SHP-/- mice display a distinct microbiome from the wild-
type genotype (WT) through alterations in the ratio of Firmicutes to Bacteroidetes with changes 
in phylogenetic diversity.   
 
Materials and Methods 
 Mouse Studies.  Separate cages consisted of a single genotype of littermates, and 
cohoused cages consisted of equal numbers of WT C57BL/6NHsd and SHP-/- mice also based on 
a C57BL/6NHsd background.  Age-matched mice were housed in cages of four, and cohoused 
cages were set up immediately after weaning at three weeks of age.  Cohoused cages were used 
to reduce microbiome-associated differences and isolate the physiological differences associated 
with the altered bacterial composition.  All cages were housed in a temperature and light-
controlled room on a 12-hour light-dark cycle (06:30 on, 18:30 off).  Diet and water was 
available ad libitum, consisting of either laboratory chow (5001, Lab Diet, MO) for chow diet 
(CD) or WD consisting of high sucrose and 42% energy from saturated fats (TD.88137, Harlan 
Labs, IN).  All mice were fed CD until WD was introduced at eight weeks of age and fed to mice 
for twenty-four weeks.  Body weight was taken on average every seven days following WD 
administration.  After twelve total weeks of WD, a glucose tolerance test was performed after 
overnight fasting.  Following intraperitoneal injection of 1 g/kg glucose solution, blood glucose 
was checked at thirty minute intervals for two hours using a Bayer Contour Next EZ handheld 
blood glucose meter (Bayer HealthCare, IN).  After fourteen total weeks of western diet, mouse 
body composition was determined using an EchoMRI machine (EchoMRI, TX).  All animals 
were handled humanely, and all protocols were approved by the Institutional Animal Care and 
Use Committee at NEOMED. 
Tissue Collection and Measurement of Gene Expression.  Tissue collection was 
performed after 6 months of WD feeding.  Liver samples were used for gene expression, from 
which total RNA was isolated using a TRIzol solution (Life Tech, NY) [31].  cDNA was 
synthesized from total RNA using PrimeScript RT master mix (Clontech, CA), and qPCR was 
run to determine mRNA levels using an Applied Biosystems Gene Amp PCR System 9700 real-
time PCR machine with iTaq Universal SYBR supermix (both from BioRad, CA).  GAPDH was 
used as an internal control, and relative expression was determined from ΔCt values normalized 
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to the expression of separate WT mice fed CD.  Primer sequences were obtained from 
http://pga.mgh.harvard.edu/primerbank, and the pathway flowchart used PathVisio v3.2.1 [5]. 
Gut Microbiome Profiling.  Fecal samples were collected for all cages immediately 
before initiation of WD, and again after ten weeks of WD feeding.  Mice were placed into an 
autoclave-sterilized cage for thirty-six hours with sterilized water and normal diet to maintain 
microbiome consistency.  All feces was collected in a laminar flow hood, and stored at -80oC 
until use.  Bacterial DNA was then extracted using a Fecal DNA MiniPrep kit (Zymo Research, 
CA), and PCR was performed using primers targeting the V3 and V4 region of the 16S rRNA 
gene (Integrated DNA Technologies, IA).  The primer list is found in Table 1.  Pippin Prep 
cassettes (1.5% agarose) were used for purification and targeted DNA collection (Sage Science, 
MA), and purified samples were quantified via Qubit spectroscopy (Qubit Systems, ON, Canada) 
using a dsDNA high-sensitivity assay kit (Invitrogen-ThermoFisher, NY).  Samples were sent to 
the Advanced Genetic Technologies Center (University of Kentucky, Lexington) for Illumina 
MiSeq tag pyrosequencing run on a dual-indexed, 250 base pair flowcell (Illumina, CA).  Using 
QIIME v1.9.1, output files were demultiplexed, and operational taxonomic unit (OTU) picking 
was done using an open-reference algorithm [32, 33].  For samples with greater than 104,006 
sequence count, beta diversity principal coordinates analysis was estimated using unweighted 
UniFrac and Adonis Permanova to measure significance (p-value) and an effect size (R2) to 
explain variation, and 
rarefied alpha diversity 
using Faith’s phylogenetic 
diversity (PD) whole tree 
analysis [2, 4].  Unless 
specified otherwise, a 
homoscedastic Student’s t-
test was used to compare 
two different groups, where 
P < 0.05 was considered 
significantly different.  
Values are averages ± SD 
unless otherwise listed. 
Table 1: The list of primers used for Illumina PCR (IDT, IA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
The adapter, pad, linker, and gene-specific primer sequence is common within 
the forward and the reverse primers.  The barcode indices are used to generate 
a unique string for paired-end sequencing that is recognized for sorting OTU 
sequences [4]. 
Name 5’                           Illumina Adapter Sequence Barcode Index Pad Linker Gene Specific Primer         3’
F1) AATGATACGGCGACCACCGAGATCTACAC ATCGTACG TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
F2) AATGATACGGCGACCACCGAGATCTACAC ACTATCTG TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
F3) AATGATACGGCGACCACCGAGATCTACAC TAGCGAGT TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
F4) AATGATACGGCGACCACCGAGATCTACAC CTGCGTGT TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
F5) AATGATACGGCGACCACCGAGATCTACAC TCATCGAG TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
F6) AATGATACGGCGACCACCGAGATCTACAC CGTGAGTG TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
F7) AATGATACGGCGACCACCGAGATCTACAC GGATATCT TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
F8) AATGATACGGCGACCACCGAGATCTACAC GACACCGT TATGGTAATT GT GTGCCAGCMGCCGCGGTAA
Name 5’                           Illumina Adapter Sequence Barcode Index Pad Linker Gene Specific Primer         3’
R1) CAAGCAGAAGACGGCATACGAGAT AACTCTCG AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
R2) CAAGCAGAAGACGGCATACGAGAT ACTATGTC AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
R3) CAAGCAGAAGACGGCATACGAGAT AGTAGCGT AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
R4) CAAGCAGAAGACGGCATACGAGAT CAGTGAGT AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
R5) CAAGCAGAAGACGGCATACGAGAT CGTACTCA AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
R6) CAAGCAGAAGACGGCATACGAGAT CTACGCAG AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
R7) CAAGCAGAAGACGGCATACGAGAT GGAGACTA AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
R8) CAAGCAGAAGACGGCATACGAGAT GTCGCTCG AGTCAGTCAG CC GGACTACHVGGGTWTCTAAT
Forward primers (515F-IL)
Reverse primers (806R-IL)
Mifflin 6 
 
Results and Discussion 
Cohousing genotypes alters body weight gain.  In order to explore a potential linkage between 
microbiome and the lean phenotype observed in SHP-/- mice, this experiment cohoused WT and 
SHP-/- mice.  It was expected that the coprophagic tendencies of mice would lead to sharing of 
gut bacteria, and previous studies have reported complete sharing of microbiome population 
within four weeks [34].  Body weight from separate cages matched previous studies, as the 
deletion of SHP was associated with significantly reduced weight gain upon WD feeding (Fig. 
1C) [1].  Cohousing led to a dramatic decrease in the protection from body weight increases (Fig. 
1B & 1D) in SHP-/- mice, as mice fed CD or WD displayed a nearly equalized average body 
weight between genotypes.  This suggests the role of the gut bacteria in the protection upon SHP 
deletion from DIO formation. 
Fig. 1: Body weight changes associated with cohousing WT and SHP-/- mice over the experimental period, beginning 
with the day WD was first administered at eight weeks of age.  Values are average of total body weight per cage ± SD 
for each group (n=4 for all).  Student’s homoscedastic t-test was used for significance, where P < 0.05 was considered 
significant.   
B A 
D C 
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Deletion of SHP alters the microbiome.  Sequencing of mouse feces was then performed to 
examine the changes in bacterial composition in the guts of both separated and cohoused 
animals.  It was known that WD feeding and DIO led to an increase in the abundance of 
Firmicutes and a decreased abundance of Bacteroidetes, but the specific effect of SHP deletion 
on the gut microbiome was previously unknown [35].  Sequencing of the gut microbiome before 
and after feeding WD for 10 weeks revealed an altered bacterial composition due to diet, mouse 
genotype, and cohoused caging condition.  Following 10 weeks of WD feeding, significantly 
distinct clusters of microbiome composition were seen between genotypes in separated cages 
(Supp. Fig. 2A).  Cohousing cages alleviated these genotype-associated clusters, although 
significantly different clustering due to diet alterations remained (Supp. Fig. 2B).  Age-
associated changes in the microbiome, independent of diet, concurred with previous studies as 
well, as significantly distinct clusters appeared for both genotype and time (Supp. Fig. 2C & 2D) 
[36-38].  This suggests that diet may be a more potent influence on the microbiome than 
genotype. 
On CD, the phylogenetic diversity of sequenced samples was not significantly different, 
although SHP-/- mice tended to display a slight reduction of diversity (Fig. 2A).  However, ten 
weeks of WD feeding led to decreased diversity, as expected for both SHP-/- and WT mice (Fig. 
2B) [35].  Cohoused cages display further reductions in diversity resulting from the deletion of 
SHP (Fig. 2C).  Additionally, the deletion of SHP led to an increased diversity with CD feeding 
that was reversed upon WD feeding (Fig. 2B).  The deletion of SHP was also linked to a reduced 
OTU ratio of Firmicutes to Bacteroidetes, regardless of time period or diet (Fig. 2D).  One 
exception was seen in cohoused SHP-/- mice upon 10 weeks of WD feeding, which displayed a 
drastic increase in Firmicutes.  This difference may reflect the increased Firmicutes abundance 
typically associated with WD feeding, although this dysbiosis was not uniform for all mice fed 
WD for 10 weeks [35, 39, 40].  It is hypothesized that these effects may be caused by alterations 
in the bile acid pool caused by the deletions of SHP and WD feeding seen in previous studies [3, 
13]. 
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Sequencing of the microbiome composition revealed that the sum of Firmicutes and 
Bacteroidetes phyla account for 80-90% abundance on average, where the dominant bacteria 
were consistently from classes Clostridia and Bacilli of the Firmicutes phylum, and class 
Bacteroidia of the Bacteroidetes phylum (Supp. Fig. 3).  Mice lacking SHP consistently 
displayed large increases of class Bacteroidia with proportional decreases in Clostridia, 
regardless of diet and length of diet.  However, cohoused SHP-/- mice fed WD for 10 weeks 
Fig. 2: Analysis of sequencing samples (n=4 for all groups) 
with greater than 104,006 sequence count.  Values presented 
are average + or – SD, where half confidence intervals are 
shown to increase visibility.  Mice are grouped by caging-
time period to compare the effects of diet alteration upon the 
loss of SHP.  Student’s homoscedastic t-test was used for 
significance: # P < 0.05 and ## P < 0.01 for diet (CD-WD), 
* P < 0.05 and ** P < 0.01 for genotype (WT-SHP-/-), and ^ 
P < 0.05 for caging (separate-cohoused) significance.  (A) 
Rarefied alpha diversity using Faith’s PD for separate cages 
on CD before WD feeding began.  No significance was 
noticed for all data sets [2].  (B) Faith’s PD after 10 weeks 
of WD feeding for separate cages.  (C) Faith’s PD for 
cohoused cages after 10 weeks of WD feeding.  (D) Ratio of 
Firmicutes to Bacteroidetes, measured by a ratio of OTU 
count from sequenced feces.  The groups are separated by 
caging (Sep = Separate caging, and Co = Cohoused caging) 
and time length of WD feeding to compare the effects of diet 
alteration upon the deletion of SHP.  Caging and diet are not 
significant (P > 0.05). 
D 
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displayed a dramatic increase in Clostridia that reflect the large increases seen in the 
Firmicutes/Bacteroidetes ratio (Fig. 2D).  However, there were several specific examples that 
differed from previous studies.  Increases in Erysipelotrichi class abundance have been linked to 
the formation of hepatic steatosis and atherosclerosis formation, as the bacteria metabolize 
choline into trimethylamine, which is then converted to toxic trimethylamine N-oxide in 
hepatocytes and triggers cholesterol accumulation [7, 41].  In this study, only cohoused cages 
displayed a markedly increased abundance in the Erysipelotrichi class, independent of genotype 
and dietary alterations.  Lastly, the deletion of SHP protected from increases in Bacilli 
abundance upon feeding WD, as increases are associated with the formation of DIO [38].  
Further analysis of sequencing data is also required to glean further knowledge from gut bacteria 
changes.  Sequencing after a longer period of WD feeding would show long-term effects of 
chronic WD feeding and complement the gene expression results [35, 37].  Phylogenetic analysis 
could be carried out with current data to build a tree comparing sample groups.  To complement 
relative ratios of bacterial OTUs presented, total number of fecal bacteria should be obtained 
through either microscopy with fluorescent dye to target bacteria, or qPCR on the DNA extracted 
from fecal samples using general primers to target the 16S rRNA gene [42, 43]. 
 
Cohoused caging reduces phenotypic differences.  To explore the whole-body effects associated 
with these microbiome changes, physiological testing was performed.  As expected, SHP-/- mice 
are also protected from body fat accumulation when compared to WT mice (Fig. 3A), even on 
the liver (Fig. 3G) [1, 3].  However, cohoused mice displayed little differences from separated 
cages in their body percentage of fat and lean mass (Fig. 3A & 3B) and liver weight (Fig. 3G).  
This suggests that cohousing of SHP-/- mice was associated with loss of protection from fat 
accumulation but independent of formation of hepatic steatosis.  Although the deletion of SHP 
typically results in greater glucose intolerance upon WD feeding, little difference in insulin 
resistance was noticed between genotype, diet, or caging following a glucose tolerance test after 
3 months of WD feeding (Fig. 3C-F).  However, SHP-/- mice in separated cages fed CD in this 
study displayed an abnormally increased tolerance (Fig. 3C) while no differences were noticed in 
cages fed WD or cohoused (Fig. 3D-F) [1].  The increased similarity in body weight with 
cohoused cages may be associated with the reduced genotypic difference in phylogenetic 
diversity (Fig. 2A-C) and principal coordinates analysis clustering (Supp. Fig. 2).  The large  
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Fig. 3: Phenotype changes associated with differences in genotype over the experimental period.  Each chart contains one diet 
and caging condition, to compare differences associated with the loss of SHP, where sample number is equal (n=4) for all 
groups and tests (Sep = Separate Caging, and Co = Cohoused caging).  Student’s homoscedastic t-test was used to calculate 
significance for all tests.  # P < 0.05, ## P < 0.01, and ### P < 0.001 for diet (CD-WD); * P < 0.05, ** P < 0.01, and *** P < 
0.001 for genotype (WT-SHP-/-); ^ P < 0.05 and ^^ P < 0.01 for caging (Separate-Cohoused).  (A) Body composition through 
lean and fat percentage of total body weight measured by EchoMRI after fourteen weeks of WD feeding.  Values are the 
average ± SD.  (C, D, E, F)  Glucose tolerance test performed after twelve weeks of WD feeding via peritoneal injection of 1 
g/kg glucose solution with blood glucose measurements every thirty minutes afterward.  Values are average + or – SD, where 
half confidence intervals are shown to increase visibility between groups.  (C) Glucose tolerance test for separate mice fed CD.  
(D) Glucose tolerance test for cohoused mice fed CD.  (E) Glucose tolerance test for separate mice fed WD.  (F)  Glucose 
tolerance test for cohoused mice fed WD.  (G) Liver weight as percent of total body weight after six months of WD feeding 
following tissue collection.  Values are the average percent body weight ± SD. 
D 
F E 
C 
G 
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abundance of Firmicutes in the cohoused SHP-/- mice fed WD for 10 weeks reflected the loss of 
protection from fat accumulation, as a large abundance of Firmicutes is usually seen in mice with 
DIO and increased body weight (Fig. 2D) [11, 35, 39].  However, cohousing buffered the loss of 
diversity typically seen with WD feeding, which may protect from development of DIO (Fig. 
2C) [35].  Insulin resistance testing proved inconclusive, as WD feeding failed to show 
previously published resistance in mice lacking SHP (Fig. 3C-F) [1].  Future experiments could 
focus on liver triglyceride and cholesterol quantification to complement the liver size presented 
in this study.  Hepatic lipidomics may also help explore the molecular lipid differences under 
each caging, genotype, and diet condition, as increased levels of ceramides and other fatty acids 
have been linked to the formation of insulin resistance [44-46]. 
 
Cohousing alters hepatic gene expression for β-oxidation, and fatty acid and bile acid synthesis.  
Testing of hepatic gene expression was performed to determine the relationship of metabolic 
phenotype with alterations in the microbiome.  As SHP is involved in the repression of the bile 
acid synthesis, enzymes for both the classical and alternate pathways were tested [3, 5].  Genes 
involved in β-oxidation were also tested, as the deletion of SHP protects from hepatic steatosis 
due to increases in β-oxidation gene expression [1, 3].  Lastly, expression of genes for the 
synthesis of fatty acids and the accumulation of lipid droplets was tested, as the deletion of SHP 
downregulates both pathways [1].  In the separate cages of this study, the deletion of SHP led to 
significantly increased expression of bile acid synthesis genes from both the classical and 
alternate pathways (Fig. 4A), and the SHP-/- mice displayed greater protection from fatty acid 
synthesis and lipid droplet formation (Fig. 4B).  Surprisingly, this protection was independent of 
β-oxidation, as SHP-/- mice did not display the significantly upregulation of genes involved in β-
oxidation upon WD feeding as previous studies have shown (Fig. 4C) [1].  Cohousing mice led 
to a generalized reduction in gene expression for bile acid, fatty acid, and lipid droplet synthesis 
without altering the protection associated with the loss of SHP, suggesting the shared influence 
of genetics and microbiome in the metabolic profile. 
 Contrary to previous studies, hepatic SHP gene expression was found to increase upon 
WD feeding (Fig. 4A) [1].  Additionally, cohousing led to increases in SHP expression, causing 
greater repression of CYP7A1 expression for bile acid synthesis in WT mice (Fig. 4A).  
Derepression by the loss of SHP leads to increased expression of the three tested bile acid 
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synthesis genes, CYP7A1, CYP8B1, and CYP7B1 (Fig. 4A) [1, 17].  However, cohoused mice 
fed WD displayed a near-zero expression of the major bile acid synthesis genes from both 
pathways, which will require further testing to elucidate the both the responsible mechanism and 
its impact on the composition of the bile acid pool.  Bile acid metabolomics could also be 
performed in the lab of Dr. Leah Shriver (University of Akron, Department of Chemistry) to 
elucidate specific composition of the bile acid, especially given the drastic reductions of bile acid 
synthesis seen in cohoused mice fed WD (Fig. 4A).   
 WD feeding in separate cages led to increased expression of hepatic genes involved in 
synthesis of fatty acids (FAS) and formation of lipid droplets (CIDEC) for both genotypes, 
where the deletion of SHP protected from the significant increases seen in WT mice (Fig. 4B) [1, 
44, 47].  Cohoused cages displayed reduced overall expression of both FAS and CIDEC, 
although the protection associated with the loss of SHP remained.  The hepatic β-oxidation gene 
expression of CPT1A and ACOX1 (Fig. 4C) largely agreed with previous studies for separate 
cages [1].  However, separate WT mice fed WD displayed an abnormally high expression of 
ACOX1, signifying the possible dysregulation of fatty acid metabolism, as CIDEC expression is 
also increased.  Cohoused cages display an altered expression, as WD feeding reduces the 
expression of both genes with the loss of protection associated to the loss of SHP (Fig. 3G).  
These reductions in CIDEC expression should suggest that the altered microbiome from 
cohousing result in reduced formation of hepatic steatosis (Fig. 4B) [24].  However, the reduced 
expression of fatty acid synthesis genes upon cohousing did not influence the overall liver 
weight, suggesting that overall levels of steatosis are unaffected (Fig. 3G). 
 In the future, gene expression of tissue samples from the ileum may also be used to 
examine genes involved with absorption of bile acid, transport into the circulatory system, and 
the strength of the intestinal barrier.  Intestinal FAS gene expression induces de novo lipogenesis 
and promotes intestinal barrier strength, where reduced expression leads to increased leakiness 
that allows bacterial byproducts to enter circulation and increases cytokines involved in 
inflammation [41].  Bacterial byproducts absorbed into the circulatory system can activate Toll-
like receptors, such as LPS activating Toll-like receptor 4, resulting in a release of cytokine 
proteins like IL-1β that induce inflammation [9, 48].  In the liver, IL-1β leads to the activation of 
TNFα, which can induce hepatic steatosis [41, 48].   
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A 
B 
C 
Fig. 4: Hepatic gene expression profile 
after six months of WD feeding.  Charts 
are grouped (n=6 for cohoused WD cage, 
n=4 for all other groups) by diet and 
caging condition, to directly compare 
differences associated with SHP deletion.  
SHP itself was checked, as well as bile 
acid synthesis for the classical pathway 
(CYP7A1 and CYP8B1) and alternate 
pathway (CYP7B1).  β-oxidation gene 
expression was checked for mitochondrial 
(CPT1A) and peroxisomal (ACOX1).  
Fatty acid synthesis gene expression was 
checked for palmitate synthesis (FAS) and 
lipid droplet accumulation (CIDEC).  
Values were obtained from qPCR ∆Ct 
values with GAPDH internal control, and 
normalized to the expression of separate 
WT mice fed only CD for relative gene 
expression.  Values are averages ± SD.  
Student’s homoscedastic t-test was used to 
determine significance: # P < 0.05 and ## 
P < 0.01 for diet (CD-WD), * P < 0.05 and 
** P < 0.01 for genotype (WT-SHP-/-), and 
^ P < 0.05 and ^^ P < 0.01 for caging 
(separate-cohoused). 
Mifflin 14 
 
Summary.  This study revealed that SHP-/- mice displayed a distinct microbiome from WT mice, 
manifested in principal coordinates analyses, a significantly reduced Firmicutes/Bacteroidetes 
ratio, and loss of phylogenetic diversity upon WD feeding.  Protection from hepatic steatosis 
upon the deletion of SHP, seen through reduced liver percentage of total body weight, was 
mediated by downregulation of fatty acid synthesis and lipid droplet formation, although the 
expected increases in β-oxidation were not noticed.  SHP-/- mice also displayed derepression of 
genes in bile acid synthesis. 
Cohousing of WT and SHP-/- genotypes alleviated the loss of phylogenetic diversity seen 
in SHP-/- mice.  The protection from DIO in SHP-/- mice was also reduced upon cohousing, as 
genotypic differences in body weight and fat accumulation were lost.  However, these body 
weight changes were not associated with altered protection from the development of hepatic 
steatosis.  Cohousing resulted in generalized repression of the hepatic gene expression for β-
oxidation and synthesis of fatty acids, lipid droplets, and bile acids, where WD feeding caused 
significantly greater reductions in gene expression for bile acid synthesis.  However, the effects 
of SHP deletion on gene expression were still present in cohoused cages, as mice lacking SHP 
still displayed increases in bile acid synthesis gene expression and decreases in expression of 
genes involved in synthesis of fatty acids and lipid droplets.   
In conclusion, this study revealed that the protection from DIO and hepatic steatosis from 
the deletion of SHP was associated with alterations in the gut microbiome and altered gene 
expression.  Furthermore, cohousing WT and SHP-/- genotypes to equalize the gut bacteria led to 
decreased protection from DIO upon SHP deletion while maintaining protection from hepatic 
steatosis.  
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Supplemental Figures 
Supp. Fig. 1: Simplified bile acid synthesis pathway, showing only the major proteins for each 
conversion, and sites of SHP inhibition.  The major metabolites are shown in blue boxes/text, 
primary bile acids are yellow-green, major enzymes are black, and regulatory proteins to 
highlight the involvement of SHP in negative feedback are red.  (Adapted from [17, 49]). 
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Supp. Fig. 2: Three-dimensional principal coordinates analysis plots made with QIIME using 
unweighted UniFrac beta-diversity data from samples with greater than 104,006 sequences each.  
Sample size is listed next to each color coordination for combination of genotype and diet 
condition.  Each plot shows distinct alterations in bacterial clustering related to diet, genotype, 
time, and caging.  Adonis Permanova was used to calculate the effect size and significance of 
each genotype-diet combination of samples: * P < 0.05 for diet (CD-WD), # P < 0.05 for 
genotype (WT-SHP-/-), and NS is not significant (P > 0.05).  (A) Separately caged mice after 10 
weeks of WD, comparing the effects of genotype and diet.  (B) Cohoused cages after 10 weeks 
of WD, also comparing the effects of genotype and diet.  (C) Separately caged mice only fed 
CD, comparing the microbiome composition similarities between genotype and temporal 
changes.  (D) Separately caged mice only fed WD, also comparing the microbiome composition 
similarities between genotype and temporal changes. 
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Supp. Fig. 3: Comparison of microbiome composition, via percent of class phylogeny OTU 
abundance.  Groups (n=4 for all) are separated by caging-time period combinations to directly 
compare diet changes upon the loss of SHP.  The bolded classes in the legend are three major 
classes that are consistently seen, Clostridia, Bacilli, and Bacteroidia.  These classes compose at 
least 4.50% of the microbiome on average, seen in exact compositional abundance on the right. 
Phylum Class WT CD KO CD WT WD KO WD
Actinobacteria Actinobacteria 0.00% 0.00% 0.00% 0.03%
Actinobacteria Coriobacteriia 0.10% 0.07% 0.06% 0.11%
Bacteroidetes Bacteroidia 38.27% 50.37% 37.87% 43.17%
Cyanobacteria 4C0d-2 0.46% 0.61% 0.79% 0.69%
Deferribacteres Deferribacteres 0.00% 0.17% 0.38% 0.84%
Firmicutes Bacilli 4.50% 4.93% 5.17% 4.60%
Firmicutes Clostridia 55.76% 40.94% 53.90% 48.03%
Firmicutes Erysipelotrichi 0.09% 0.26% 0.04% 0.03%
Proteobacteria Alphaproteobacteria 0.04% 0.13% 0.09% 0.23%
Proteobacteria Betaproteobacteria 0.18% 0.23% 0.12% 0.23%
Proteobacteria Deltaproteobacteria 0.14% 0.21% 0.10% 0.29%
Proteobacteria Epsilonproteobacteria 0.04% 0.09% 0.32% 0.45%
Proteobacteria Gammaproteobacteria 0.00% 0.00% 0.01% 0.00%
Tenericutes Mollicutes 0.03% 0.12% 0.94% 0.99%
Verrucomicrobia Verrucomicrobiae 0.16% 1.23% 0.08% 0.08%
Other Other 0.23% 0.61% 0.12% 0.20%
Separate 0 Weeks
Phylum Class WT CD KO CD WT WD KO WD
Actinobacteria Actinobacteria 0.00% 0.00% 0.00% 0.00%
Actinobacteria Coriobacteriia 0.08% 0.08% 0.04% 0.04%
Bacteroidetes Bacteroidia 39.99% 44.65% 37.02% 57.49%
Cyanobacteria 4C0d-2 1.06% 0.21% 0.08% 0.09%
Deferribacteres Deferribacteres 0.00% 0.06% 0.17% 0.34%
Firmicutes Bacilli 3.26% 16.61% 4.29% 0.96%
Firmicutes Clostridia 53.96% 36.87% 55.20% 38.05%
Firmicutes Erysipelotrichi 0.08% 0.30% 0.27% 0.13%
Proteobacteria Alphaproteobacteria 0.10% 0.04% 0.02% 0.05%
Proteobacteria Betaproteobacteria 0.32% 0.21% 0.01% 0.02%
Proteobacteria Deltaproteobacteria 0.13% 0.19% 2.17% 1.57%
Proteobacteria Epsilonproteobacteria 0.10% 0.05% 0.01% 0.02%
Proteobacteria Gammaproteobacteria 0.00% 0.00% 0.20% 0.12%
Tenericutes Mollicutes 0.19% 0.01% 0.01% 0.00%
Verrucomicrobia Verrucomicrobiae 0.37% 0.20% 0.26% 1.03%
Other Other 0.34% 0.51% 0.24% 0.09%
Separate 10 Weeks
Phylum Class WT CD KO CD WT WD KO WD
Actinobacteria Actinobacteria 0.00% 0.00% 0.00% 0.05%
Actinobacteria Coriobacteriia 0.05% 0.08% 0.14% 0.10%
Bacteroidetes Bacteroidia 42.38% 52.79% 46.94% 29.68%
Cyanobacteria 4C0d-2 0.39% 0.49% 0.31% 0.03%
Deferribacteres Deferribacteres 0.04% 0.05% 0.10% 0.80%
Firmicutes Bacilli 1.82% 3.70% 2.57% 0.68%
Firmicutes Clostridia 53.60% 38.47% 46.54% 59.30%
Firmicutes Erysipelotrichi 0.46% 0.81% 1.26% 0.52%
Proteobacteria Alphaproteobacteria 0.06% 0.05% 0.04% 0.03%
Proteobacteria Betaproteobacteria 0.07% 0.18% 0.01% 0.05%
Proteobacteria Deltaproteobacteria 0.21% 0.21% 1.58% 2.93%
Proteobacteria Epsilonproteobacteria 0.08% 0.08% 0.03% 0.04%
Proteobacteria Gammaproteobacteria 0.00% 0.00% 0.09% 0.01%
Tenericutes Mollicutes 0.07% 0.12% 0.00% 0.00%
Verrucomicrobia Verrucomicrobiae 0.04% 2.01% 0.19% 5.52%
Other Other 0.72% 0.96% 0.22% 0.26%
Cohoused 10 Weeks
